NCT05450562 is a Phase 1, PHASE2 clinical trial of SAR444200 in Neoplasm, sponsored by Sanofi.

Who is sponsoring NCT05450562?

NCT05450562 is sponsored by Sanofi.

What drugs are being tested in NCT05450562?

Interventions in NCT05450562: SAR444200, Atezolizumab.

Is NCT05450562 still recruiting?

NCT05450562 is currently terminated. Last updated 14 January 2026.

Last reviewed 2026-01-14 · How we verify

NCT05450562

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

Terminated Phase 1, PHASE2 Last updated 14 January 2026

What this trial tests

Phase 1, PHASE2 trial testing SAR444200 in Neoplasm in 33 participants. Terminated before completion.

Timeline

20 September 2022

Primary endpoint
22 December 2025

22 December 2025

Quick facts

Lead sponsor	Sanofi
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	20 September 2022
Primary completion	22 December 2025
Estimated completion	22 December 2025
Sites	13 locations across South Korea, Canada, China, Singapore, United States

Drugs / interventions tested

SAR444200 — full drug profile →
Atezolizumab (atezolizumab) — full drug profile →

Conditions studied

Neoplasm — all drugs for Neoplasm →

Sponsor

Sanofi — full company profile →

Who can join

18 and older, any sex, with Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is Phase 1/Phase 2, open label, multiple cohort, first-in-human study to evaluate safety, PK, PDy and efficacy of SAR444200 as a monotherapy or in combination with other anti-cancer agents for participants aged at least 18 years with previously treated metastatic malignancies.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years.
Alexander E, Leong KW. · · 2024 · cited 83× · PMID 39455963 · DOI 10.1186/s12951-024-02900-y
Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions.
Mullin M, McClory J, Haynes W, Grace J, et al · · 2024 · cited 20× · PMID 38666503 · DOI 10.1080/19420862.2024.2341443
The basic biology of NK cells and its application in tumor immunotherapy.
Jiang P, Jing S, Sheng G, Jia F. · · 2024 · cited 17× · PMID 39221244 · DOI 10.3389/fimmu.2024.1420205
Nanobodies and their derivatives: pioneering the future of cancer immunotherapy.
Li H, Zhou Q, Cao N, Hu C, et al · · 2025 · cited 16× · PMID 40474230 · DOI 10.1186/s12964-025-02270-4
Focusing on CD8<sup>+</sup> T-cell phenotypes: improving solid tumor therapy.
Yao Z, Zeng Y, Liu C, Jin H, et al · · 2024 · cited 14× · PMID 39342365 · DOI 10.1186/s13046-024-03195-5
Bispecific Antibodies in Solid Tumors: Advances and Challenges.
Shan KS, Musleh Ud Din S, Dalal S, Gonzalez T, et al · · 2025 · cited 12× · PMID 40565299 · DOI 10.3390/ijms26125838
Targeting Glypican-3 for Liver Cancer Therapy: Clinical Applications and Detection Methods.
Zhang J, Li R, Tan X, Wang C. · · 2025 · cited 9× · PMID 40862283 · DOI 10.14218/jcth.2025.00099
Current landscape of T-cell engagers in early-phase clinical development in solid cancers.
Spinazzola A, Iannantuono GM, Gulley JL, Giudice E, et al · · 2025 · cited 3× · PMID 41122165 · DOI 10.3389/fimmu.2025.1665838

Verify or expand the search:

Other recruiting trials for Neoplasm

Currently open trials in the same condition.

NCT07447089 — EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study · NA · recruiting
NCT06739655 — Preoperative Radiation Therapy and Immediate Breast Reconstruction · NA · recruiting
NCT06813235 — Dream2Heal: An Adaptive Stepped-care Intervention for Chinese Cancer Survivors With Mild-to-moderate Insomnia · NA · recruiting
NCT06759649 — A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies · Phase 1 · recruiting
NCT06980012 — Evaluation of the Impact of the Clinical Pharmacist in Oral Therapies in Oncology. · NA · recruiting

Other Sanofi trials

Trials by the same sponsor.

NCT07282795 — Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe · not yet recruiting
NCT06694025 — Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe. · not yet recruiting
NCT07222189 — A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Dise · Phase 2 · not yet recruiting
NCT07484230 — A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Partic · Phase 3 · not yet recruiting
NCT07547436 — A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age Wi · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05450562 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sanofi
Last refreshed: 14 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05450562.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing